2CUREX AB SEK-10 (2QE) - Total Assets
Based on the latest financial reports, 2CUREX AB SEK-10 (2QE) holds total assets worth €5.18 Million EUR (≈ $6.05 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 2CUREX AB SEK-10 shareholders equity for net asset value and shareholders' equity analysis.
2CUREX AB SEK-10 - Total Assets Trend (2021–2024)
This chart illustrates how 2CUREX AB SEK-10's total assets have evolved over time, based on quarterly financial data.
2CUREX AB SEK-10 - Asset Composition Analysis
Current Asset Composition (December 2024)
2CUREX AB SEK-10's total assets of €5.18 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 66.7% |
| Accounts Receivable | €2.61 Million | 33.8% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how 2CUREX AB SEK-10's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is 2CUREX AB SEK-10 worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 2CUREX AB SEK-10's current assets represent 100.0% of total assets in 2024, an increase from 99.1% in 2021.
- Cash Position: Cash and equivalents constituted 66.7% of total assets in 2024, down from 92.2% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 33.8% of total assets.
2CUREX AB SEK-10 Competitors by Total Assets
Key competitors of 2CUREX AB SEK-10 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Crispr Therapeutics AG
NASDAQ:CRSP
|
USA | $2.73 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
2CUREX AB SEK-10 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.14 | 1.51 | 1.51 |
| Quick Ratio | 1.14 | 1.51 | 1.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €626.00K | €2.18 Million | €2.18 Million |
2CUREX AB SEK-10 - Advanced Valuation Insights
This section examines the relationship between 2CUREX AB SEK-10's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 63.13 |
| Latest Market Cap to Assets Ratio | 0.47 |
| Asset Growth Rate (YoY) | 9.0% |
| Total Assets | €7.70 Million |
| Market Capitalization | $3.63 Million USD |
Valuation Analysis
Below Book Valuation: The market values 2CUREX AB SEK-10's assets below their book value (0.47x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: 2CUREX AB SEK-10's assets grew by 9.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for 2CUREX AB SEK-10 (2021–2024)
The table below shows the annual total assets of 2CUREX AB SEK-10 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €7.70 Million ≈ $9.01 Million |
+8.95% |
| 2023-12-31 | €7.07 Million ≈ $8.27 Million |
-85.16% |
| 2022-12-31 | €47.66 Million ≈ $55.72 Million |
-39.80% |
| 2021-12-31 | €79.16 Million ≈ $92.55 Million |
-- |
About 2CUREX AB SEK-10
2cureX AB (publ) operates as a medical technology company in Europe. The company's principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient's tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.